



BAFNA PHARMACEUTICALS LIMITED

Regd. Office. No.299 Thambu Chetty Street, Chennai-600 001.

Tel.No. 044-25267517 / Fax No. 044-25231264.

Sales
up by
62.45%

Net
Profit
up by
132.46

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2010

(Rs. In Lakhs)

Sl. No.	PARTICULARS	Quarter Ended		Year Ended	
		31.03.2010 (Audited)	31.03.2009 (Audited)	31.03.2010 (Audited)	31.03.2009 (Audited)
1	INCOME				
a	Sales	2407.62	1763.06	7440.14	4579.95
b	Other Operating Income	0.00	0.00	0.00	0.00
	Total Income (a+b)	2407.62	1763.06	7440.14	4579.95
2	EXPENDITURE				
a	(Increase) / Decrease in Stock in Trade & Work in Progress	517.95	223.98	(81.91)	200.17
b	Consumption of Raw materials	1676.89	1200.93	6297.42	3569.55
c	Employee Cost	43.98	49.00	235.30	154.22
d	Depreciation	42.00	-93.15	173.79	137.15
e	Other Expenditure	53.24	25.05	209.70	144.89
f	Total	2334.06	1405.81	6834.30	4205.98
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	73.56	357.25	605.84	373.97
4	Other Income	27.90	50.41	77.99	145.42
5	Profit before Interest and exceptional Items (3+4)	101.46	407.66	683.83	519.39
6	Interest & Bank Charges	-3.21	67.14	231.86	206.13
7	Profit(+)/Loss(-) after Interest but before Exceptional Items (5-6)	104.67	340.52	451.97	313.26
8	Exceptional Items	12.96	0.00	55.44	65.73
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)	91.71	340.52	396.53	247.53
10	Tax Expenses	148.38	141.03	148.38	140.78
11	Net Profit(+)/Loss(-) from Ordinary Activities After Tax (9-10)	-56.67	199.49	248.15	106.75
12	Extraordinary Items	0.00	15.14	0.00	0.00
13	Net Profit(+)/Loss(-) for the period (11-12)	-56.67	184.35	248.15	106.75
14	Paid up Equity Share Capital	1598.13	1598.13	1598.13	1598.13
	Face Value of the Share	10.00	10.00	10.00	10.00
15	Reserves excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year				2254.19
16	Earnings per Share (EPS) :	-0.35	1.25	1.55	1.08
a	Basic and diluted EPS Before Extraordinary Items	-0.35	1.15	1.55	0.67
b	Basic and diluted EPS After Extraordinary Items				
17	Public Share Holding :				
	Number of Shares	7940392	8062356	7940392	8062356
	Percentage of Share Holding	49.69	50.45	49.69	50.45
18	Promoters and promoter group				
a	Pledged/Encumbered	NIL	NIL	NIL	NIL
	Number of Shares				
	Percentage of shares (as a % of the total share holding of promoter and promoter group)	NIL	NIL	NIL	NIL
	Percentage of shares (as a % of the total share capital of the company)				
b	Non-encumbered				
	Number of Shares	8040943	7128729	8040943	7918979
	Percentage of shares (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00
	Percentage of shares (as a % of the total share capital of the company)	50.31	44.61	50.31	49.55

NOTES

- The above audited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 28th May, 2010.
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The figures for the previous periods have been regrouped wherever necessary.
- Status of investor Complaints.:

Pending at the beginning of the quarter	Nil
No. of complaints received and disposed off during the quarter	Nil
Complaints pending at the end of the quarter	Nil

For and on behalf of the Board of Directors,

Place: Chennai
Date: 28.05.2010

Signed
BAFNA MAHAVEER CHAND
Chairman and Managing Director